Malignant histiocytomas, originating from histiocytes, present diverse locations and require multimodal treatment. This study shows a 62.5% survival rate in 16 patients, highlighting treatment efficacy.
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
The histiogenesis of malignant histiocytomas and related neoplasms has been debated.
A common cell of origin, the histiocyte, is hypothesized for these heterogeneous tumors.
Purpose of the Study:
To investigate the clinical characteristics and treatment outcomes of malignant histiocytomas.
To evaluate the efficacy of surgical and chemotherapeutic interventions.
Main Methods:
Retrospective review of 16 patients diagnosed with malignant histiocytomas between 1966 and 1974.
Analysis of tumor locations, surgical procedures, and adjuvant therapies including cobalt therapy and chemotherapy (vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride, chlorambucil).
Main Results:
Tumors were identified in various locations, including extremities, head, chest wall, retroperitoneum, lung, spermatic cord, and lower abdomen.
Treatment modalities included radical amputations, wide local excision, pulmonary lobectomy, nephrectomy, cobalt therapy, and chemotherapy.
Of 16 patients, 10 survived without evidence of disease, 2 survived with metastatic disease, and 4 succumbed to the malignancy.
Conclusions:
Malignant histiocytomas demonstrate diverse presentations and locations.
Multimodal treatment approaches, including surgery and chemotherapy, can achieve significant survival rates for patients with malignant histiocytomas.
